Moreover, in a in vivo model of Glioma, Tang et al., proposed a complex therapy based on a combinatory approach of an adoptive cell transfer of tumor-specific CD8+ cells (to increase adoptive T cell targeting of the tumor), rapamycin (to enhance antigen presentation by DCs), celecoxib (to modulate the TME inflammation and immunosuppression), and intratumoral injection of IL15Rα-IL15-armed oncolytic poxviruses (to boost T cell activation) (205). The gene discussed is CD8A; the disease is central nervous system cancer.